CNSP - CIK 0001729427
CNS Pharmaceuticals, Inc. has filed 379 documents with the SEC between 2018 and 2026. The most frequent type is major company event (98 filings), alongside the regular cadence of annual reports, quarterly reports, and event disclosures every public company must make. Use the filters to focus on one filing type, or flip the sort to trace the company's history from its earliest paperwork.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Filing | Type | Filed | Period covered |
|---|---|---|---|
| EFFECT | - | 2026-05-26 | - |
| 424B3 | - | 2026-05-26 | - |
| Insider trade | 4 | 2026-05-20 | 2026-05-18 |
| D | - | 2026-05-19 | - |
| Securities registration | S-3 | 2026-05-19 | - |
| SCHEDULE 13G/A | - | 2026-05-15 | - |
| Quarterly report | 10-Q | 2026-05-14 | 2026-03-31 |
| Major company event | 8-K | 2026-05-04 | 2026-05-04 |
| Annual report (amended) | 10-K/A | 2026-04-30 | 2025-12-31 |
| SCHEDULE 13G | - | 2026-04-17 | - |
| Annual report | 10-K | 2026-03-31 | 2025-12-31 |
| Major company event | 8-K | 2026-03-11 | 2026-03-11 |
| Insider trade | 4 | 2026-03-04 | 2026-03-02 |
| New insider ownership | 3 | 2026-03-04 | 2026-03-02 |
| Insider trade | 4 | 2026-03-04 | 2026-03-02 |
| New insider ownership | 3 | 2026-03-04 | 2026-03-02 |
| Major company event | 8-K | 2026-03-02 | 2026-02-26 |
| Employee stock plan | S-8 | 2026-02-27 | - |
| Major company event | 8-K | 2026-02-17 | 2026-02-10 |
| SCHEDULE 13G/A | - | 2026-02-13 | - |
| Insider trade | 4 | 2026-01-02 | 2026-01-01 |
| New insider ownership | 3 | 2026-01-02 | 2026-01-01 |
| Major company event | 8-K | 2025-12-17 | 2025-12-16 |
| Major company event | 8-K | 2025-11-21 | 2025-11-17 |
| Insider trade | 4 | 2025-11-19 | 2025-11-17 |
| Insider trade | 4 | 2025-11-19 | 2025-11-17 |
| Insider trade | 4 | 2025-11-19 | 2025-11-17 |
| Insider trade | 4 | 2025-11-19 | 2025-11-17 |
| Insider trade | 4 | 2025-11-19 | 2025-11-17 |
| Insider trade | 4 | 2025-11-19 | 2025-11-17 |
| Insider trade | 4 | 2025-11-19 | 2025-11-17 |
| Quarterly report | 10-Q | 2025-11-14 | 2025-09-30 |
| SCHEDULE 13G/A | - | 2025-11-14 | - |
| Proxy materials | DEFA14A | 2025-11-12 | - |
| SCHEDULE 13G | - | 2025-11-04 | - |
| Annual report to shareholders | ARS | 2025-10-28 | 2024-12-31 |
| Proxy statement | DEF 14A | 2025-10-24 | 2025-11-17 |
| PRE 14A | - | 2025-10-10 | 2025-11-17 |
| Prospectus supplement | 424B5 | 2025-09-19 | - |
| Quarterly report | 10-Q | 2025-08-14 | 2025-06-30 |
| SCHEDULE 13G | - | 2025-08-14 | - |
| Major company event | 8-K | 2025-07-22 | 2025-07-17 |
| Major company event | 8-K | 2025-07-15 | 2025-07-15 |
| Quarterly report | 10-Q | 2025-05-15 | 2025-03-31 |
| Major company event | 8-K | 2025-05-15 | 2025-05-13 |
| 424B4 | - | 2025-05-14 | - |
| EFFECT | - | 2025-05-13 | - |
| Company correspondence | CORRESP | 2025-05-12 | - |
| Company correspondence | CORRESP | 2025-05-12 | - |
| S-1/A | - | 2025-05-12 | - |